Bioscience Company Secures $14 Million Grant For Clinical Development of Opioid Treatment

The opioid crisis is one of the most pressing public health challenges in the United States and globally. Characterized by alarming rates of addiction and overdose deaths, this crisis demands innovative solutions that can balance effective pain management with minimizing the risk of abuse and overdose. In this context, Ensysce Biosciences, Inc. has emerged as a frontrunner in developing novel opioid technologies aimed at addressing these dual challenges. Recently, the company received a $14 million multi-year grant from the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) to advance the clinical development of PF614-MPAR, a groundbreaking opioid with built-in overdose protection. $Ensysce Biosciences (ENSC.US)$